Johnson & Johnson is preparing to test experimental vaccines against HIV in the United States and Europe that seek to achieve the development of the first immunization against deadly diseases after decades of frustration.
About 3,800 men who have sex with other men will receive a vaccine regimen in a study that will be launched later this year, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in the United States, said in an interview.
The HIV Vaccine Test Organization organization and nonprofit agency will collaborate with J & J Janssen units in this initiative.
Since the case began to get attention in the early 1980s, Scientists have not managed to make a vaccine against the virus that causes AIDS and kill nearly one million people worldwide every year.
Efforts continue and at least two other promising candidates with studies at the final stage are calculated.
J & J seeks to produce vaccines that work in populations throughout the world infected with various types of viruses that change rapidly. Other experimental vaccines have focused on preventing individual variants.
That approach "takes us one step closer to encompassing a large diversity of viruses worldwide," said Dan Barouch, a professor at Harvard Medical School, whose research laid the foundation for the vaccine. "
For medical and public health reasons around the world, it's better to have vaccines that function in several parts of the world. "
"The cost of treating patients with HIV, the burden on patients, the burden on society is very high," said Paul Stoffels, scientific director of J & J. HIV prevention is "a big mission for us. We have been working on it for almost 30 years."
The World Health Organization (WHO) aims to reduce HIV-related deaths worldwide to less than half a million next year and vaccines are considered a fundamental tool to end the AIDS epidemic here until 2030.
However, efforts to develop immunization are partly frustrated because the virus mutates very quickly.